title: Commentary on an article by Kyucheol Noh, MD, et al.: "Targeting inflammatory kinase as an adjuvant treatment for osteosarcomas".
authors.affiliation: Orthopaedic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
authors.forename: John H
authors.initials: JH
authors.lastname: Healey
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D016923:Cell Death / Q000187:drug effects; D002470:Cell Survival; D004317:Doxorubicin / Q000494:pharmacology; D005419:Flavonoids / Q000494:pharmacology*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000201:enzymology; D051379:Mice; D008819:Mice, Nude; D019950:Mitogen-Activated Protein Kinase 1 / Q000037:antagonists & inhibitors*; D048052:Mitogen-Activated Protein Kinase 3 / Q000037:antagonists & inhibitors*; D012516:Osteosarcoma / Q000188:drug therapy* / Q000201:enzymology*; D018579:Patient Selection; D015996:Survival Rate; D049490:Systems Biology; D014407:Tumor Cells, Cultured
chemical_list: D005419:Flavonoids; D004317:Doxorubicin; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one